To target the EGFR, this drug undergoes a combination of inhibitory mechanisms, and the company claims that this will allow the drug to target a broad patient population.
This drug undergoes a combination of inhibitory mechanisms. This is to target the EGFR. This will allow the drug to target a broad patient population. This is what the company claims.